CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Public ClinicalTrials.gov record NCT03292809. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
Study identification
- NCT ID
- NCT03292809
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 328 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2017
- Primary completion
- May 21, 2018
- Completion
- Jun 19, 2018
- Last update posted
- Dec 21, 2022
2017 – 2018
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CYS-003 Investigational Site | Newport Beach | California | 92663 | — |
| CYS-003 Investigational Site | Torrance | California | 90505 | — |
| CYS-003 Investigational Site | Indianapolis | Indiana | 46290 | — |
| CYS-003 Investigational Site | Louisville | Kentucky | 40206 | — |
| CYS-003 Investigational Site | Andover | Massachusetts | 01810 | — |
| CYS-003 Investigational Site | Raynham | Massachusetts | 02767 | — |
| CYS-003 Investigational Site | Memphis | Tennessee | 38119 | — |
| CYS-003 Investigational Site | Nashville | Tennessee | 37205 | — |
| CYS-003 Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03292809, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2022 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03292809 live on ClinicalTrials.gov.